Insulin Management

Cross-source consensus on Insulin Management from 1 sources and 5 claims.

1 sources · 5 claims

Dosage & preparation

Participants with screening HbA1c from 7.0% to below 8.0% receive about a 10% reduction in total daily insulin dose before randomisation. — Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting
Hypoglycaemia and diabetic ketoacidosis are major safety concerns in type 1 diabetes if insulin is reduced too aggressively during tirzepatide treatment. — Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting
Participants with screening HbA1c above 8.0% receive no initial insulin adjustment. — Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting
The trial records basal, bolus and total daily insulin dose changes from week -4 to week 76. — Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting
DAFNE training is considered important because it teaches safe insulin adjustment during illness and when starting treatments such as tirzepatide. — Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting